健康志愿者口服和静脉注射纳布啡的药代动力学。
The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.
作者信息
Aitkenhead A R, Lin E S, Achola K J
机构信息
University Department of Anaesthesia, Leicester Royal Infirmary.
出版信息
Br J Clin Pharmacol. 1988 Feb;25(2):264-8. doi: 10.1111/j.1365-2125.1988.tb03300.x.
Abstract
The pharmacokinetics of nalbuphine were studied in 10 healthy volunteers on two separate occasions following administration by either the intravenous (20 mg) or oral (60 mg) route. After administration, serum concentrations of nalbuphine were measured for 12 h using a high pressure liquid chromatography assay, and pharmacokinetic parameters were derived using a three compartment model. After i.v. administration, elimination half-life was 222 (111-460) min (mean and range) and total body clearance was 1.5 (0.8-2.3) 1 min-1.Cmax after oral administration was 21.4 (6.0-36.2) ng ml-1 and tmax was 46.6 (15.3-89.0) min. Bioavailability of the oral preparation was 11.8 (6.1-20.1)%.
摘要
在10名健康志愿者身上，分两次通过静脉注射（20毫克）或口服（60毫克）途径给药后，对纳布啡的药代动力学进行了研究。给药后，使用高压液相色谱分析法在12小时内测定纳布啡的血清浓度，并使用三室模型推导药代动力学参数。静脉注射给药后，消除半衰期为222（111 - 460）分钟（均值和范围），全身清除率为1.5（0.8 - 2.3）升/分钟。口服给药后的Cmax为21.4（6.0 - 36.2）纳克/毫升，tmax为46.6（15.3 - 89.0）分钟。口服制剂的生物利用度为11.8（6.1 - 20.1）%。
相似文献
1
The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.健康志愿者口服和静脉注射纳布啡的药代动力学。
Br J Clin Pharmacol. 1988 Feb;25(2):264-8. doi: 10.1111/j.1365-2125.1988.tb03300.x.
2
The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers.
J Clin Pharmacol. 1987 Nov;27(11):866-73. doi: 10.1002/j.1552-4604.1987.tb05581.x.
3
The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.健康受试者中静脉注射、肌肉注射及皮下注射纳布啡的药代动力学。
Eur J Clin Pharmacol. 1987;33(3):297-301. doi: 10.1007/BF00637566.
4
Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.
Clin Pharmacol Ther. 1989 Aug;46(2):226-33. doi: 10.1038/clpt.1989.130.
5
[Elimination of nalbuphine in human milk].
Arzneimittelforschung. 1988 Oct;38(10):1496-8.
6
Species variation in the disposition of nalbuphine and its acetylsalicylate ester analogue.纳布啡及其乙酰水杨酸酯类似物处置过程中的物种差异。
Xenobiotica. 1988 Nov;18(11):1239-47. doi: 10.3109/00498258809042247.
7
The effect of aging on the pharmacokinetics of nalbuphine in rabbits.衰老对纳布啡在兔体内药代动力学的影响。
Biopharm Drug Dispos. 1995 Nov;16(8):695-703. doi: 10.1002/bdd.2510160808.
8
Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).盐酸纳布啡对伊斯帕尼奥拉亚马逊鹦鹉（Amazona ventralis）静脉注射和肌肉注射后的药代动力学
Am J Vet Res. 2011 Jun;72(6):741-5. doi: 10.2460/ajvr.72.6.741.
9
Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia.直肠内注射纳布啡在接受全身麻醉儿童中的药代动力学
Fundam Clin Pharmacol. 1997;11(2):133-7. doi: 10.1111/j.1472-8206.1997.tb00180.x.
10
[Cumulative pharmacokinetics and clinical effects of nalbuphine in patients in the postoperative phase. An open multicenter study].[纳布啡在术后患者中的累积药代动力学及临床效果。一项开放性多中心研究]
Arzneimittelforschung. 1989 Jun;39(6):724-7.
引用本文的文献
1
Disposition of Oral Nalbuphine and Its Metabolites in Healthy Subjects and Subjects with Hepatic Impairment: Preliminary Modeling Results Using a Continuous Intestinal Absorption Model with Enterohepatic Recirculation.口服纳布啡及其代谢产物在健康受试者和肝损伤受试者中的处置：使用具有肠肝循环的连续肠道吸收模型的初步建模结果
Metabolites. 2024 Aug 27;14(9):471. doi: 10.3390/metabo14090471.
2
A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate.一种用于预测健康人体中药物肠肝再循环的连续肠道吸收模型：纳布啡作为模型底物。
Mol Pharm. 2024 Sep 2;21(9):4510-4523. doi: 10.1021/acs.molpharmaceut.4c00424. Epub 2024 Jul 2.
3
Efficacy and Safety of Parenteral Injection of an Extended Release κ-receptor Opioid Sebacoyl Dinalbuphine Ester for Acute and Chronic Pain After Laparoscopic Bariatric Surgery: a Randomized, Placebo-Controlled, Double-Blind Trial.注射用延伸释放κ型阿片受体激动剂塞来昔布丁钠酯治疗腹腔镜减重手术后急性和慢性疼痛的有效性和安全性：一项随机、安慰剂对照、双盲试验。
Obes Surg. 2023 Apr;33(4):1192-1201. doi: 10.1007/s11695-023-06502-9. Epub 2023 Feb 14.
4
Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants.纳布啡经鼻内或静脉给药在婴儿中的药代动力学和耐受性。
Arch Dis Child. 2023 Jan;108(1):56-61. doi: 10.1136/archdischild-2022-323807. Epub 2022 Sep 13.
5
Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study.纳布啡与吗啡治疗儿童癌症疼痛的副作用比较：一项前瞻性研究。
Cancers (Basel). 2022 Jul 25;14(15):3617. doi: 10.3390/cancers14153617.
6
Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants.鼻内和静脉注射纳布啡的药代动力学分析以优化婴儿疼痛管理
Front Pediatr. 2022 Mar 2;10:837492. doi: 10.3389/fped.2022.837492. eCollection 2022.
7
Determination of Nalbuphine Hydrochloride in Pharmaceutical Formulations Using Diperiodatoargentate(III)-Rhodamine-B Chemiluminescence System by Flow Injection Analysis.流动注射分析-高碘酸钠（III）-罗丹明 B 化学发光体系测定药物制剂中盐酸纳布啡的含量。
Anal Sci. 2020 Oct 10;36(10):1223-1227. doi: 10.2116/analsci.20P126. Epub 2020 May 22.
8
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.盐酸纳布啡缓释片在血液透析患者中的药代动力学及对瘙痒的探索性作用
BMC Nephrol. 2015 Apr 8;16:47. doi: 10.1186/s12882-015-0043-3.
9
Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.常用辅料可调节尿苷二磷酸葡萄糖醛酸转移酶2b7的活性，以提高纳布啡在人体中的口服生物利用度。
Pharm Res. 2014 Jul;31(7):1676-88. doi: 10.1007/s11095-013-1272-4. Epub 2014 Feb 14.
10
[Analgesia with opioids in the paediatric patient.].[儿科患者的阿片类药物镇痛。]
Schmerz. 1992 Dec;6(4):229-38. doi: 10.1007/BF02527811.
本文引用的文献
1
Ceiling effect for respiratory depression by nalbuphine.纳布啡引起呼吸抑制的天花板效应。
Clin Pharmacol Ther. 1980 Apr;27(4):478-85. doi: 10.1038/clpt.1980.67.
2
High-performance liquid chromatographic analysis of plasma levels of nalbuphine in cardiac surgical patients.心脏手术患者血浆中纳布啡水平的高效液相色谱分析。
J Chromatogr. 1982 Dec 10;233:410-6. doi: 10.1016/s0378-4347(00)81777-6.
3
The enflurane sparing effect of morphine, butorphanol, and nalbuphine.吗啡、布托啡诺和纳布啡对安氟醚的节省效应。
Anesthesiology. 1982 Dec;57(6):489-92. doi: 10.1097/00000542-198212000-00010.
4
Analgesic effect of intramuscular and oral nalbuphine in postoperative pain.肌肉注射和口服纳布啡对术后疼痛的镇痛效果。
Clin Pharmacol Ther. 1981 Feb;29(2):174-80. doi: 10.1038/clpt.1981.28.
5
Nalbuphine and droperidol combination for local standby sedation.纳布啡与氟哌利多联合用于局部备用镇静。
Anesthesiology. 1983 Apr;58(4):397. doi: 10.1097/00000542-198304000-00034.
6
Anesthetic potency of nalbuphine and interaction with morphine in rats.
Anesth Analg. 1981 Sep;60(9):629-33.
7
Determination of nalbuphine in human plasma by automated high-performance liquid chromatography with electrochemical detection.
Res Commun Chem Pathol Pharmacol. 1984 Jan;43(1):159-68.
8
Detection of nalbuphine in plasma: an improved high-performance liquid chromatographic assay.血浆中纳布啡的检测：一种改进的高效液相色谱法
J Chromatogr. 1984 Nov 9;311(1):223-6. doi: 10.1016/s0378-4347(00)84714-3.
9
Evaluation of nalbuphine for abuse potential.纳布啡滥用可能性评估。
Clin Pharmacol Ther. 1972 Jan-Feb;13(1):78-90. doi: 10.1002/cpt197213178.
10
Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs.口服和直肠纳布啡的生物利用度：大鼠和犬的首过代谢
Biopharm Drug Dispos. 1985 Oct-Dec;6(4):413-21. doi: 10.1002/bdd.2510060407.
Zotero 插件